IDA in Inflammatory Bowel Disease: Pathology, Treatment Options, and the Risks of Underdiagnosis

Sponsored by The Academy for Continued Healthcare Learning (ACHL).

This activity is supported by an educational grant from American Regent.

Scroll to the Bottom of this Information to Begin this Course

Release date: November  30, 2017

Valid through: November 30, 2018

Specialty: Gastroenterology, Hematology, Oncology, Primary Care

Topic: Iron deficiency anemia (IDA)

Media: Internet

Estimated Time to Complete Activity: 30 minutes

Target Audience

This educational activity is designed for gastroenterologists, hematologists, oncologists, and other healthcare professionals treating gastrointestinal and cancer related anemia.

Program Overview

This activity will discuss the unique clinical relationship between inflammatory bowel disease (IBD) and iron deficiency anemia (IDA), including the role IBD pathology plays in blocking optimal iron absorption. Many IBD patients contend with multiple challenges and comorbidities that all can directly or indirectly lead to IDA and subsequent poor outcomes. A leading gastroenterologist will discuss IDA-related diagnostic challenges, treatment options, and management protocols for IBD patients.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Define IDA etiology, signs/symptoms, and epidemiology across patient subsets.
  • Outline established and novel treatment options for IDA, including efficacy, routes of administration, and clinical appropriateness for IDA across multiple patient subsets and clinical severity levels.
  • Analyze clinical examples of IDA and develop feasible treatment solutions based on relevant symptom severity, practice setting, and patient subset.

Credit Available

  • Physicians — maximum of 0.50 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Paul Feuerstadt, MD, FACG

Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT

Physician Continuing Medical Education

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:

Paul Feuerstadt, MD, FACG
  • Consulting Agreements: Merck & Co.
  • Speakers' Bureau: Allergan, Entera Health, Inc. and Merck & Company
  • Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: This activity discusses common off-label uses of IV iron formulations for treatment of iron-deficiency anemia across multiple patient subsets, not all of which are currently FDA-indicated to receive IV iron. Practitioners are advised to use appropriate caution, and consult the FDA black-box safety warnings on several currently available IV iron products and formulations.

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Instructions for Participation and Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the activity and complete the post-test and evaluation form. To receive credit, 60% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Inquiries may be directed to ACHL at (877) 444-8435, ext. 228.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.